2009-09-06 - Bioglan in Sweden is sold to Reig Jofré in Spain
Bioglan is as of September 1st part of the Spanish group Reig Jofré.
Bioglan AB is a contract development and manufacturing organisation founded 1984 in Malmö, Sweden. Bioglan is specialised in development and manufacture of topical pharmaceutical products. Bioglan was until end of August a subsidiary of Midelfart Sonesson, whose focus is on food supplements, health, natural remedies, common cold and hygiene. Bioglan’s focus has and will continue to be pharmaceuticals and medical device registered products. Both Midelfart Sonesson and Bioglan are in agreement this is a very good solution to ensure the best potential for continued growth.
The acquisition of the Bioglan assets was made by the family-owned Reig Jofré Group founded 1929 in Barcelona, Spain. RJ Group is one of the largest Spanish developer, and manufacturer, of pharmaceuticals for third parties, and has taken a strategic decision to grow internationally. RJ Group is highly specialised in injectable and oral antibiotics, as well as sterile freeze drying. RJ Group has historically developed, manufactured and marketed a portfolio of dermatological products that will expand with the acquisition of Bioglan.
Bioglan AB has 50 employees and they are all offered continued employment as part of RJ Group. RJ Group will, with this transaction, employ close to 600 people globally. In 2009, the annual group turnover is expected to approach 100M€.
Bioglan AB is a CDMO (Contract Development and Manufacturing Organisation) and provides support for pharmaceutical and life science companies in all aspects of development and manufacture of semi-solids and liquids, mainly used for topical applications. Bioglan collaborates with companies of all sizes, from the smallest start-up companies to the leading pharmaceutical houses within topical applications mainly in dermatology and is acting on an international market. The services include formulation & analytical development, small scale manufacture and supply for clinical trials, commercial manufacture, registration support, quality control and quality assurance.
Bioglan’s own products, with leading trademarks such as Crystacide and Synalar, which are developed and manufactured at Bioglan AB, will continue to be distributed worldwide through already existing partners. On the Scandinavian market Bioglan will continue to supply products sold under trademarks such as Amosyt, Capsina, Crystacide, Hibitane, LHP, Metosyn, Micanol, Microcid, Synalar and Tenutex.
For further information on Bioglan please contact:
Totte Malmström, CEO, Bioglan AB, tel +46 40 287575 (office) / +46 70 725 725 8 (mobile) www.bioglan.se
Ignasi Biosca Reig, CEO, Reig Jofré, tel +34934806706 (office)/ +34610711758 (mobile) www.reigjofre.com